Prostate Cancer Clinical Trials in Chicago, Illinois

21 studies are recruiting for prostate cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago, Illinois
    Locations
    303 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    38 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  3. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Illinois Cancer Center, Chicago, Illinois
    Locations
    96 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  4. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Hospital, Chicago, Illinois
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  5. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

    The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    Northwestern University, Chicago, Illinois
    Locations
    106 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06855277 on ClinicalTrials.gov

  6. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Chicago, Illinois
    Locations
    346 in total
    Run by
    AstraZeneca

    See if you can join NCT06952803 on ClinicalTrials.gov

  7. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    University of Chicago, Chicago, Illinois
    Locations
    93 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

  8. A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

    Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk pros…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Chicago Comprehensive Cancer Center, Chicago, Illinois
    Locations
    4 in total
    Run by
    University of Chicago

    See if you can join NCT05726292 on ClinicalTrials.gov

  9. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    19 in total
    Run by
    Pathos AI, Inc.

    See if you can join NCT06785636 on ClinicalTrials.gov

  10. PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

    1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard th…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Rush MD Anderson, Chicago, Illinois
    Locations
    6 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT06274047 on ClinicalTrials.gov

  11. Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

    The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois
    Run by
    University of Chicago

    See if you can join NCT05790213 on ClinicalTrials.gov

  12. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    University of Illinois at Chicago, Chicago, Illinois
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  13. Clinical Trial of Approaches to Prostate Cancer Surgery

    This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have simil…

    Stage
    Not phased
    Ages
    40 to 80
    Site
    Northwestern University, Chicago, Illinois
    Locations
    9 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05155501 on ClinicalTrials.gov

  14. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  15. Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

    The purpose of this research is to gather information on the safety and effectiveness of using an imaging technique called magnetic resonance imaging (MRI) to decrease radiation dose to the uninvolved prostate (areas of the prostate that do not clearly have cancer cells) while increasing radiation …

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
    Run by
    University of Chicago

    See if you can join NCT06171269 on ClinicalTrials.gov

  16. GU-01: Glycyrrhizin in Prostate Cancer

    This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Illinois, Chicago, Illinois
    Run by
    University of Illinois at Chicago

    See if you can join NCT06378346 on ClinicalTrials.gov

  17. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  18. Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

    This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not re…

    Stage
    Not phased
    Ages
    70 and older
    Site
    The University of Illinois at Chicago (UIC), Chicago, Illinois
    Locations
    2 in total
    Run by
    University of Chicago

    See if you can join NCT06824818 on ClinicalTrials.gov

  19. Geriatric Assessment and Technology Evaluation in Prostate Cancer

    By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also…

    Stage
    Not phased
    Ages
    Any age
    Site
    o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
    Run by
    University of Chicago

    See if you can join NCT06215508 on ClinicalTrials.gov

  20. FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

    The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are: Does FK-PC101 delay or …

    Stage
    Phase 2
    Ages
    Any age
    Site
    University of Chicago Medicine, High-Risk and Advanced Prostate Cancer Clinic, Chicago, Illinois
    Locations
    3 in total
    Run by
    Cellvax Therapeutics Inc

    See if you can join NCT06636682 on ClinicalTrials.gov

  21. Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

    Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in > 90% of cases. However, at th…

    Stage
    Phase 4
    Ages
    18 to 80
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    3 in total
    Run by
    Albany Medical College

    See if you can join NCT05629494 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.